natera™ | Signatera™ Residual disease test (MRD)

BREAST CANCER

Know more sooner

Signatera™ enables patient monitoring in the critical window (<5 years) when breast cancer patients are more likely to recur

Tumor-informed ctDNA testing for MRD assessment to help answer important clinical questions in the adjuvant and surveilling settings

Signatera™ Molecular Residual Disease assay is covered by Medicare for monitoring disease progression, disease recurrence, or relapse for patients with:

- Stage II-IV breast cancer in the neo-adjuvant setting
- Stage IIb and higher breast cancer across all subtypes, including hormone receptor (HR)-positive, HER2-positive, and triple negative breast cancers within the adjuvant and surveillance settings
- Signatera™ enables access to MRD testing at critical time points within their treatment journey

Demonstrated leadership in ctDNA monitoring for MRD in breast cancer	
Relapse sensitivity in breast cancer	88%[1]
Median lead time over radiographic recurrence	10.5 mos[1]

Use Signatera™ to identify patients with residual disease who may benefit from additional treatment

Adjuvant treatment

Risk stratify patients after surgery to help identify those with residual disease who may benefit from adjuvant treatment for high risk individuals

Surveillance setting

Monitor and help detect recurrence ahead of conventional tools with serial ctDNA testing in high risk patients

Immunotherapy

Monitor ctDNA serially to help identify response/ non response to immunotherapy and clarify indeterminate imaging

References: 1. . Shaw JA, et al. Serial postoperative ctDNA monitoring for early detection of breast cancer recurrence DOI:10.1200/JCO.2022.40.16_suppl.562 *Journal of Clinical Oncology* (June 01, 2022) 40:16_suppl, 562-562. *As of June 2023

Know cancer's next move in breast cancer

Get the broadest access to industry leading MRD assessment for patients with breast cancer, regardless of subtype

natera™ | Signatera™ Residual disease test (MRD)



Validated performance[2,9]

Across **>4,000 patients, >25 tumor types,** and **>40 peer-reviewed publications**

Prognostic of disease recurrence and progression; predictive of IO treatment benefit

Extensive experience helping power treatment decisions[1]

>150,000 Signatera™ patients **>275,000** MRD time points evaluated

>30% of US oncologists have ordered Signatera™

Optimized for longitudinal monitoring

Signatera™ **quantifies ctDNA** via mean tumor molecules per mL (MTM/mL) of plasma to **assess real-time changes in disease burden**

Broadest payer coverage*

Signatera™ is covered by Medicare for **CRC**, **breast cancer**, and **MIBC**, and **pan-cancer immunotherapy response monitoring**

References: 1. Natera data on file **2.** Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nature Cancer. 2020;1(9):873-881. **3.** Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019. **4.** Coombes RC, Page K, Salari R, et al. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clin Cancer Res. 2019;25(14):4255-4263. **5.** Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. **6.** Christensen E, Birkenkamp-Demtroder K, Sethi H, et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. J Clin Oncol. 2019;37(18):1547-1557. **7.** Kotani D. et al., Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer, Nature Medicine v29 Issue 1 Jan 2023. **8.** Shirasu et.al , Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan. ASCO GI July 2021. **9.** Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021. *As of June 2023

Discover more here at: natera.com/oncology

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

Signatera™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved. SGN_PC_MRDLeadership_BreastCancer_9x6_20240305_NAT-9000209